BioAtla, Inc. (BCAB): Price and Financial Metrics


BioAtla, Inc. (BCAB): $10.41

0.56 (+5.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BCAB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BCAB Stock Price Chart Interactive Chart >

Price chart for BCAB

BCAB Price/Volume Stats

Current price $10.41 52-week high $25.43
Prev. close $9.85 52-week low $2.01
Day low $9.74 Volume 455,200
Day high $10.50 Avg. volume 766,104
50-day MA $7.88 Dividend yield N/A
200-day MA $5.64 Market Cap 391.49M

BioAtla, Inc. (BCAB) Company Bio


BioAtla LLC develops conditionally active biologic antibody therapeutics. The firm's technologies include conditionally active biologics, comprehensive integrated antibody optimization, CPE and CPS, gigamab, and versitop. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.


BCAB Latest News Stream


Event/Time News Detail
Loading, please wait...

BCAB Latest Social Stream


Loading social stream, please wait...

View Full BCAB Social Stream

Latest BCAB News From Around the Web

Below are the latest news stories about BIOATLA INC that investors may wish to consider to help them evaluate BCAB as an investment opportunity.

Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to a 259.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 15, 2022

Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | November 11, 2022

BioAtla to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Scott Smith, President and Sheri Lydick, Senior Vice President, Commercial Strategy will participate in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held in London, UK November 1

Yahoo | November 8, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting off the final day of trading this week with a look at the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | November 4, 2022

BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates

BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 4, 2022

Read More 'BCAB' Stories Here

BCAB Price Returns

1-mo 51.09%
3-mo 23.93%
6-mo 278.55%
1-year -58.77%
3-year N/A
5-year N/A
YTD -46.97%
2021 -42.28%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6818 seconds.